Potential applications for rhIGF-I: Bone disease and IGFI.

  title={Potential applications for rhIGF-I: Bone disease and IGFI.},
  author={Marisol Bahamonde and Madhusmita Misra},
  journal={Growth hormone \& IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society},
  • M. Bahamonde, M. Misra
  • Published 23 March 2020
  • Medicine, Biology
  • Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
Insulin-Like Growth Factor I (IGF-I); cytoprotective effects, idea of replacement therapy in the healthy elderly subjects
The general functional properties of IGF-I and implications of its possible use as a replacement to the healthy elderly subjects are discussed and its downfalls and new perceptions are emphasis.
Low Serum 25-hydroxyvitamin D Level Does Not Adversely Affect Bone Turnover in Prepubertal Children
It seems that serum 25(OH)D level may not be an adequate predictor of bone turnover in children, as it explained 15% of the IGF-1 variance and 6%" of the P1NP variance.
Effects of high-dose all-trans retinoic acid on longitudinal bone growth of young rats.
The Effect of Diabetes Mellitus on IGF Axis and Stem Cell Mediated Regeneration of the Periodontium
This review outlines the most recent updates in characterizing MSCs isolated from diabetics to fully understand why diabetic patients are more prone to periodontitis that theoretically reflect the impaired regenerative capabilities of their native stem cells.
Effects of Dietary Phytoestrogens on Hormones throughout a Human Lifespan: A Review
The results of human studies on dietary phytoestrogens are summarized with the aim of assessing the possible hormone-dependent outcomes and health effects of their consumption throughout a lifespan, focusing on pregnancy, childhood, adulthood, and the premenopausal and postmenopausal stages.


Effects of rhIGF-1 administration on surrogate markers of bone turnover in adolescents with anorexia nervosa.
Effects of recombinant human IGF-I and oral contraceptive administration on bone density in anorexia nervosa.
These data demonstrate that osteopenic women with anorexia nervosa treated withrhIGF-I showed more beneficial changes in bone density, compared with patients not treated with rhIGf-I, which is not sufficient to improve bone density in undernourished patients.
Effects of short-term recombinant human insulin-like growth factor I administration on bone turnover in osteopenic women with anorexia nervosa.
It is hypothesized that short term administration of recombinant human IGF-I (rhIGF-I) would increase bone turnover in young women with anorexia nervosa and there was a significant increase in markers of bone formation, as assessed by both PICP and OC.
Regulation of skeletal growth and mineral acquisition by the GH/IGF-1 axis: Lessons from mouse models.
  • S. YakarO. Isaksson
  • Biology, Medicine
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2016
Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
In this patient with severe insulin resistance, therapy with rhIGF-I resulted in beneficial effects on Si, body composition, bone size, and linear growth, which have implications for IGF-I therapy in a variety insulin resistant states.
Fibroblast growth factor-21 may mediate growth hormone resistance in anorexia nervosa.
FGF-21 levels are higher in AN independent of the effects of percent body fat and insulin resistance, and the inverse association between elevated FGF- 21 levels and IGF-I suggests that above the normal range, F GF-21 may mediate a state of GH resistance in AN.
Bone Mineral, Histomorphometry, and Body Composition in Adults with Growth Hormone Receptor Deficiency
Bone mineral content and density were significantly lower in adults with GHRD than in controls, and volumetric bone density was preserved despite low levels of IGF‐I and IGFBP‐3 associated with GH resistance, confirming the importance of the GH/IGF axis in regulating bone size and body composition.
Reduced Serum IGF‐1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass
The reduced serum IGF‐1 associated with hepatic osteodystrophy is a main determinant of low cortical but not trabecular bone mass in the Li‐GHRKO‐HIT mice.
Circulating levels of IGF-1 directly regulate bone growth and density.
The double gene disruption LID+ALSKO mouse model demonstrates that a threshold concentration of circulating IGF-1 is necessary for normal bone growth and suggests that IGF- 1, IGFBP-3, and ALS play a prominent role in the pathophysiology of osteoporosis.
Increases in IGF-1 After Anti–TNF-&agr; Therapy Are Associated With Bone and Muscle Accrual in Pediatric Crohn Disease
Short-term improvements in IGF-1 z scores predicted recovery of bone and muscle outcomes following initiation of anti-TNF-α therapy in pediatric CD, and suggest that disease effects on growth hormone metabolism contribute to musculoskeletal deficits in CD.